Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)

Konstanze Spieth, Roland Kaufmann, Reinhard Dummer, Claus Garbe, Jürgen C. Becker, Axel Hauschild, Wolfgang Tilgen, Selma Ugurel, Michael Beyeler, E.‐b. Bröcker, Katharina C. Kaehler, Claudia Pföhler, Jens Gille, Ulrike Leiter, Dirk SchadendorfAnnals 2008 · DOI

BibTeX
@article{spieth2008temozolomide,
  author = {Konstanze Spieth and Roland Kaufmann and Reinhard Dummer and Claus Garbe and Jürgen C. Becker and Axel Hauschild and Wolfgang Tilgen and Selma Ugurel and Michael Beyeler and E.‐B. Bröcker and Katharina C. Kaehler and Claudia Pföhler and Jens Gille and Ulrike Leiter and Dirk Schadendorf},
  title = {{Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)}},
  journal = {Annals},
  year = {2008},
  doi = {10.1093/annonc/mdm565},
}

Loading related content...

Figure